National Bank of Canada
SRNE

National Bank of Canada’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

National Bank of Canada’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,250
Closed -$1.1K – 2933
2022
Q4 		$1.1K Hold
1,250
– – ﹤0.01% 2577
2022
Q3 		$2K Hold
1,250
– – ﹤0.01% 2562
2022
Q2 		$3K Hold
1,250
– – ﹤0.01% 2574
2022
Q1 		$3K Hold
1,250
– – ﹤0.01% 2683
2021
Q4 		$6K Buy
+1,250
New +$7.76K ﹤0.01% 2516

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

National Bank of Canada's SRNE Position: Q1 2023 in Review

National Bank of Canada sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 1,250 shares — an estimated $1.1K sold.

National Bank of Canada first reported a position in SRNE in Q4 2021 and held it in 5 quarters. The position peaked at $6K in Q4 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • National Bank of Canada reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • National Bank of Canada sold 1,250 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $1.1K.
  • National Bank of Canada first reported a position in Sorrento Therapeutics, Inc. in Q4 2021 and held it in 5 quarters.
  • National Bank of Canada's Sorrento Therapeutics, Inc. position peaked at $6K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on National Bank of Canada's 13F filing for Q1 2023, filed 12 Apr 2023.